Aims Heart failure is a major medical problem in the elderly. Neurohormonal activation plays a role in the pathophysiology of heart failure, but is also affected by ageing. The present study was carried out to examine the influence of age on neurohormonal activation and prognosis in patients with chronic heart failure.
Introduction
The incidence of congestive heart failure rises dramatically in the elderly population, and heart failure is becoming an increasingly large public health problem [1] . Many morphological and physiological changes take place in the elderly, both at the cardiac and at the peripheral level [2] , and neurohormonal systems become activated [3, 4] . There is accumulating evidence that neurohormonal activation plays a role in the pathophysiology of heart failure [5] . Although there are some data on changes in neurohormones with ageing in patients with heart failure [3, 4, [6] [7] [8] their precise relationship, in particular the assessment of the interplay of a large number of currently evaluated neurohormones, has not been established. Furthermore, it is not really clear whether age alone has an (adverse) effect on prognosis [9] [10] [11] . These potential relationships are important since an increasing number of heart failure drugs are being developed to inhibit or modulate neurohormonal activation [5] , and these drugs may thus have different effects in various age groups. Whether age affects survival in heart failure is also relevant, since most large (drug) trials are biased towards recruiting younger patients than the community average, and data on the effects of such drugs in the elderly are scarce [12] . In addition to the well-known plasma neurohormones norepinephrine, epinephrine, dopamine, renin, aldosterone, and atrial natiuretic peptide, we also measured N-terminal atrial natriuretic peptide, and endothelin (-1) in the present study. The latter two neurohormones were recently shown to have additive clinical value in patients with left ventricular dysfunction and heart failure [13] [14] [15] . In response to atrial stretch, pro-atrial natriuretic peptide, which is a 126-amino-acid prohormone , is secreted and cleaved into an N-terminal peptide (N-terminal atrial natriuretic peptide ), and a C-terminal peptide [99-126] [13, 16] . C-terminal atrial natriuretic peptide, usually referred to as atrial natriuretic peptide, is biologically active, but N-terminal atrial natriuretic peptide, which has a much longer half-life [17] , is not. Endothelin-1 is released by the (vascular) endothelium and has potent and long-lasting vasoconstrictor and growth-promoting properties [18] . Two other isoforms of endothelin (ET-2 and ET-3) have been identified, as well as two different receptors (ET A and ET B ) [19] .
Patients in the present study were part of a recent large survival trial (PRIME-II: Prospective Randomized study of Ibopamine on Mortality and Efficacy) [20] . The population consisted of 372 patients with moderate to severe heart failure who were enrolled in the Netherlands, and were part of a pre-defined neurohormonal substudy.
Methods
The PRIME-II study was designed to examine the effect of the oral dopamine against, ibopamine, on all-cause mortality in patients with moderate to severe chronic heart failure [20] . The study was conducted in 13 European countries and 1906 patients were included. The present pre-defined substudy was carried out only in the Netherlands. In 23 participating centres (see Appendix), blood for plasma neurohormones was collected from 372 patients. The aim of the present study was (1) to examine the effect of ageing on plasma neurohormones, as measured at baseline, i.e. before active study drug administration, and (2) to evaluate the effect of ageing on prognosis (or survival) during the follow-up period of the study, i.e. while patients were part of the double-blind treatment in the PRIME-II study (ibopamine 3 100 mg added to their medication, or placebo). The study protocol was approved by each local Ethical Committee, and all patients gave their written informed consent before entry into the study.
Patients aged 18-80 years were eligible for PRIME-II [20] if they had signs and symptoms of moderate to severe chronic heart failure (New York Heart Association [NYHA] functional class III-IV). They were classified by their investigators as NYHA III, NYHA III/IV, or NYHA IV. Patients were required to have had symptoms at rest, or a hospital admission for heart failure, within the previous 2 months, but those who could not be discharged from hospital were not eligible. All patients had to be on optimal medical treatment for heart failure, including angiotensin converting enzyme (ACE) inhibitors (unless intolerant), diuretics (in a dose of furosemide d80 mg [or equivalent] if ACE-inhibitors were not prescribed, or d40 mg, when combined with an ACE inhibitor), and, if indicated, digoxin and vasodilators. Evidence of heart disease had to be proved by one or more of the following techniques: (a) a left ventricular ejection fraction <0·35 (measured by radionuclide or contrast ventriculography, or by echocardiography); (b) a left ventricular internal enddiastolic diameter >60 mm or a fractional shortening <20% on echocardiography, and (c) a cardiothoracic ratio on a standard chest X-ray >0·50. Exclusion criteria included: obstructive valve disease, obstructive or restrictive cardiomyopathy, any potentially transient cause of heart failure such as acute myocarditis, myocardial infarction or cardiac surgery within previous 3 months, uncontrolled arrhythmias, the need for intravenous inotropic support, known intolerance or current use of dopamine agonists, and administration of investigational drug with in the last 30 days.
Neurohormonal measurements
Blood was collected from an intravenous cannula after patients had rested in the supine position for >30 min. Samples were poured into chilled 10-ml heparized polystyrene tubes containing 12 mg of glutathione (for measurement of catecholamines, renin and aldosterone) and chilled 10 ml tubes containing EDTA (19 mg) and aprotinin (1000 kIU) (for measurement of atrial natriuretic peptide, N-terminal atrial natriuretic peptide, and endothelin). The tubes were centrifuged within 30 min (4 C, 10 min, 2000 g) and the plasma was separated and stored in polyethylene tubes at 70 C.
All plasma neurohormone samples were transported (on dry-ice) to the Core Laboratory at the University Hospital Dijkzigt, Rotterdam, the Netherlands, where all measurements were performed. Plasma norepinephrine (normal value in our laboratory 100-500 pg . ml were determined by high-performance liquid chromatography with fluorometric detection after isolation from plasma by a specific liquid-liquid extraction method and derivatization with the selective fluorogenic agent 1,2-diphenylethylenediamine [21] . Active plasma renin concentration (normal: 5-50 U . ml 1 ) was measured as previously described [22] . For measurement of aldosterone (normal 50-250 pg . ml 1 ), a commercially available kit (Coat-a-Count, Diagnostic Products Corporation, Los Angeles, CA, U.S.A.) was used [23] . Measurement of atrial natriuretic peptide (normal value: 15-35 pmol . l 1 ) and endothelin concentrations (normal 1-5 pg . ml 1 ) were performed after SepPak extraction, with commercially available radioimmunoassay kits from the Nichols Institute, Wijchen, the Netherlands, as previously described [24, 25] . Plasma N-terminal atrial natriuretic peptide (normal 150-500 pmol . l 1 ) was determined using a radioimmunoassay kit (Biotop, Oulu, Finland) [26] .
Statistical methods
The relationship between plasma neurohormones and age was examined in the 372 patients at baseline, i.e. before the start of the study. Plasma neurohormonal values were not normally distributed in the present study. Analyses were therefore conducted on the natural logarithms of the neurohormone values [6] . After this transformation, the distributions were normal or nearnormal. Pearson and Spearman correlation coefficients were calculated when appropriate. To determine the relationship between each of the plasma neurohormones with age and the markers of severity of heart failure (NYHA functional class and left ventricular ejection fraction), univariate and stepwise multiple regression analysis was performed. Multiple regression analysis was implemented by stepwise selection of other relevant baseline variables such as sex, blood pressure, heart rate, rhythm, aetiology and duration of heart failure, concomitant medication (in particular ACE-inhibitors, diuretics, digoxin, and anti-arrhythmic drugs).
The influence of age on prognosis was evaluated during the follow-up period of the PRIME II Study [20] . Cumulative rates for survival for distinct age categories were calculated by the Kaplan-Meier method. The survival rates between the age groups were compared by the Log-Rank statistic. To determine the influence of all relevant baseline characteristics on survival, Cox proportional-hazards regression analysis was performed. Only variables with P values <0·20 in the univariate Cox regression analysis were used in the multiple Cox regression analysis. In this multiple Cox regression analysis, a backward selection was employed, resulting in a model with only significant predictors for survival. To investigate whether the relationship between survival and continuous baseline variables was linear, odds ratios of the quartiles were calculated. If the odds ratios increased/decreased in a linear way, the variable was taken in the model as continuous. If linearity could not be demonstrated, the variable was categorized by taking together the quartiles with similar odds ratios. To examine in more detail linearity of the effect of age on survival, the same strategy was employed starting from 12 categories of age. The results are given as mean SD, unless indicated otherwise. All reported P values are two-tailed, and a P value <0·05 was considered statistically significant.
Results

Study population and follow-up
The clinical and demographic characteristics of the 372 patients are given in Table 1 . The mean age of the patients was 68 8 years (range 38-80). The majority of patients had coronary artery disease as the underlying aetiology (76%), and two-thirds of these patients had a previous myocardial infarction. In all but one patient, at least one measurement of left ventricular ejection fraction was available, and the majority (78%) of these measurements was made with radionuclide ventriculography. Approximately two-thirds of patients were classified as NYHA functional class III, and the rest were in NYHA class III/IV or IV. ACE inhibitors were used in 95% of patients, and diuretics in 99%; digoxin was used in almost 60% of patients, indicating that patients were on optimal medication for heart failure. Almost 20% of patients were taking an antiarrhythmic agent, of which 90% was amiodarone. There was no relationship between age and left ventricular ejection fraction; in contrast, NYHA functional class slightly increased with advancing age (P=0·04). PRIME-II was prematurely discontinued in August 1995 when a significantly higher fatality rate was observed in the ibopamine group than in the placebo group (relative risk 1·26; 95% CI 1·04-1·53; P=0·017), after which the Safety Committee advised that the study should be terminated [20] . In the final analysis of the study, 1906 patients had been randomized, who had a follow-up of slightly less than 1 year.
Plasma neurohormones
All neurohormones were measured in 369-372 patients (=99-100%), apart from endothelin, which for technical reasons could only be determined in 349 patients (94%). Most plasma neurohormone concentrations were increased in this population as compared to normal values, but mean epinephrine, dopamine and aldosterone were found to be within the normal range (Table 2 ). When the relationship between plasma neurohormone levels and the severity of heart failure was examined (Table 3) , these neurohormones generally increased as left ventricular ejection fraction decreased, while the reverse was observed with NYHA functional class. On multivariate analysis, N-terminal atrial natriuretic peptide showed the strongest relationship with left ventricular ejection fraction, while norepinephrine was most significantly related to NYHA functional class.
Effects of ageing on neurohormones
Univariate analysis showed, that norepinephrine, renin, aldosterone, atrial natriuretic peptide and N-terminal atrial natriuretic peptide were all significantly correlated with age, while epinephrine, dopamine and endothelin were not (Table 4) . N-terminal atrial natriuretic peptide, atrial natriuretic peptide and norepinephrine all significantly increased with age, with correlations of 0·31, 0·23 and 0·14, respectively. In contrast, renin and aldosterone decreased with age, and the correlations were 0·13 and 0·10, respectively. Epinephrine and dopamine were not affected, while endothelin was the least influenced by ageing (r=0·01). 0·0039  0·15  0·18  <0·0001  0·26  <0·0001  Epinephrine  0·0039  0·15  0·016  0·45  0·04  0·065  Dopamine  0·14  0·08  0·57  0·017  0·12  0·12  Renin  <0·0001  0·22  0·50  0·0008  0·17  0·17  Aldosterone  0·50  0·04  0·64  0·014  0·13  0·34  Atrial natriuretic peptide  <0·0001  0·27  0·017  0·0002  0·20  0·15  N-terminal atrial natriuretic peptide  <0·0001  0·33  0·0019  <0·0001  0·25  0·058  Endothelin  0·0008  0·18  0·061  0·015  0·13  0·64 *Pearson calculation; **Spearman calculation. On multivariate analysis only N-terminal atrial natriuretic peptide and atrial natriuretic peptide remained highly significantly correlated with age (both P<0·0001), and N-terminal atrial natriuretic peptide increased approximately three-fold from the age of 40 to 80 years (Fig. 1) .
Ageing did not significantly affect prescription patterns regarding use and dose of ACE inhibitors and diuretics, which might otherwise particularly have affected plasma renin and aldosterone.
Effects of ageing on prognosis
During a follow-up of 5-982 days (mean 354), 92 of the 372 patients died (25%). There was a non-linear relationship between age and prognosis, and the influence of age was therefore assessed by using quartiles (Fig. 2) . On univariate analysis, mortality in the highest age quartile (>74 years) was higher than those c74 years (P=0·05, risk ratio 1·5; 95% CI 1·0-2·4) (Fig. 3) . On univariate analysis, the following variables were also selected to be included in the multiple Cox regression analysis: use of high-dose diuretics (>80 mg furosemide or equivalent) vs low-dose (c80 mg furosemide) (P=0·01), use of digoxin (P=0·01), low diastolic blood pressure (P=0·01), low left ventricular ejection fraction (P=0·02), NYHA functional class (P=0·02), use of ibopamine (P=0·07), absence of use of beta-blocker (P=0·07), male gender (P=0·11), and history of hypertension (P=0·19).
On multivariate analysis, age >74 years was an independent predictor of mortality (P=0·04, risk ratio 1·9; 95% CI 1·05-3·4). In addition, use of high-dose diuretics (P=0·01) and low left ventricular ejection fraction (P=0·03) were also significantly related to increased mortality in this patient population. Neurohormones, prognosis and ageing in heart failure 757
Discussion
The main finding of the present study is that ageing affects both the pattern of neurohormonal activation and the prognosis in patients with heart failure. With regard to neurohormonal activation, the present data show that although a number of plasma neurohormones are affected by ageing on univariate analysis, only N-terminal atrial natriuretic peptide and atrial natriuretic peptide show an independent positive relationship with ageing. With regard to the effect of ageing on prognosis, it appears that while no linear increase in mortality was observed with ageing in the present analysis, heart failure patients in the oldest quartile (>74 years) had a significantly increased mortality.
Changes in plasma neurohormones with ageing
N-terminal atrial natriuretic peptide and atrial natriuretic peptide showed a highly statistically significant (P<0·0001) relationship with ageing in the present study, but the correlation was only modest (0·31 or less). Plasma norepinephrine levels also increase with ageing, and renin and aldosterone gradually decrease, but none of these relationships were statistically significant on multivariate analysis. Plasma epinephrine, dopamine and endothelin were not affected by ageing. It is tempting to speculate that in the elderly heart failure patients in the present study who had a similar systolic dysfunction (left ventricular ejection fraction) to younger patients, the (partly physiological) diastolic dysfunction may have played a role in this increase with ageing [2] . This is supported by the fact that in contrast to the similar left ventricular ejection fraction in younger and older patients, NYHA functional class increased in the elderly in the present population, which confirms recent similar observations [27] . Although both atrial natriuretic peptide and N-terminal atrial natriuretic peptide are useful parameters, N-terminal atrial natriuretic peptide appears to be superior in the clinical assessment of heart failure [13, 14] . This may be related to the fact that atrial natriuretic peptide is more rapidly cleared from plasma than N-terminal atrial natriuretic peptide, and as a result concentrations of N-terminal atrial natriuretic peptide are much higher than those of atrial natriuretic peptide. Indeed, acute haemodynamic changes are better reflected by changes in atrial natriuretic peptide, while N-terminal atrial natriuretic peptide is a more stable marker for clinical severity of disease in chronic heart failure [28] . Other advantages of N-terminal atrial natriuretic peptide are that it is technically easy to measure [26] , and that it remains stable at room temperature for at least 72 h [29] , which may allow its use in routine clinical practice.
Although it has generally been assumed that the activation of the sympathetic nervous system and the renin angiostensin system are affected by ageing [3, 6, 7] , these plasma neurohormones did not show an independent association in the present study. This finding is probably due to the fact that heart failure constitutes a complex interplay of a large number of factors, many of which may be affected by ageing. In addition to myocardial, renal, peripheral, and neurohormonal changes, the effect of drugs (such as diuretics and ACE inhibitors) may be different in younger as opposed to older patients [3, 4] . Furthermore, renin and aldosterone are also affected by the dose of ACE inhibitors and diuretics, which might be different in the elderly, but neither use nor dose of these drugs was affected by ageing in the present study. The influence of ageing on plasma endothelin has not yet been studied previously, to our knowledge. In the present study, plasma endothelin showed a significant, but modest relationship to the severity of heart failure, but this relationship was lost on multivariate analysis. Endothelin was, however, not affected by ageing, which is somewhat surprising. Peripheral flow and endothelial function decrease with ageing [27] , which might affect endothelin secretion. Further, endothelin secretion is influenced by several neurohormones [30] , which themselves are affected by ageing. The net effect, however, appears to be neutral.
Influence of age on prognosis
In the present study, there was no linear effect of age on mortality for the whole study population, i.e. there was no gradual increase in mortality as heart failure patients became older, although the size of the present investigation does not gradually exclude such a linear increase. However, in the oldest age group (>74 years), there was a significant increase in mortality, with a risk ratio of 1·9 compared to younger patients. Previous reports on the effect of age alone on survival have yielded different results. In the 2 V-HeFT Studies (in which the analysis as conducted in a similar fashion using four age groups) age alone was not associated with shortened survival in patients <75 years [9] . In contrast, data from the National Health and Nutrition Examination Survey (NHANES-I) Epidemiologic Follow-up Study showed that mortality rates in heart failure patients aged 65 to 74 years were approximately 1·5 times higher than in patients aged 55-64 years, during long-term followup [10] . In a subanalysis of the Studies of Left Ventricular Dysfunction (SOLVD), age markedly influenced all follow-up events, including mortality [11] . In that study, the risk ratio for mortality for patients aged d65 years was 1·48 compared to those aged <65 years. In contrast to these two studies [9, 10] , patients >75 years were also included in SOLVD, and total mortality was significantly higher in the oldest of the five age groups (>75 years) ( 30%), compared to 10-20% mortality in younger patients. In combination with these data, the present results therefore suggest that age becomes an important and independent contributor to mortality in the truly elderly (>75 years).
Clinical implications and limitations of the study
There is now convincing evidence that neurohormonal activation plays an important role in the pathophysiology of heart failure, and an increasing number of drugs are being developed which specifically aim at modulating these neurohormonal systems. Given the dramatic increase in heart failure in the elderly, it is surprising that only very few data are available on the age-related effects of drugs in heart failure. Both atrial natriuretic peptide and N-terminal atrial natriuretic peptide significantly increased with ageing in the present study, but only atrial natriuretic peptide is haemodynamically active, and a potential target for drug treatment. It would therefore be interesting to study the age-related effects of drugs that reduce the degradation of atrial natriuretic peptide, such as the neutral endopeptidase inhibitors. Their cardiac, renal and neurohormonal effects have recently been shown to be effective in short-term studies in heart failure [30] . In agreement with the data of previous trials in less advanced heart failure [9] [10] [11] , the present results suggest that in patients 75 years or older, ageing alone becomes an independent factor for mortality. Although this may seem logical, it implies that in heart failure drug trials which enroll a substantial proportion of elderly patients, age becomes a significant factor with regard to survival, which may limit the results obtained. Since these truly elderly patients (>75 years) represent an important part of the overall heart failure population, it is important that a substantial proportion of such patients are included in the large trials. However, to evaluate whether significant age-related differences are present in these patients pre-defined subgroup analyses should be performed.
The present findings are limited because they constitute observational data, and thus they can only be used to generate new hypotheses. Although medication was in general similar, not all patients were using the same drugs. Despite the fact that we corrected for these differences in the multivariate model, it is possible that correlations were missed. Further, it cannot be ruled out that some of the correlations between neurohormones and age would have become statistically significant if the number of patients had been higher, which also holds for the association between age and mortality if the follow-up had been longer.
